The Biosimilars Market in the US: 2019 Payer Insights Report Featuring 47 Insights Supported by 199 Directly Quoted Comments from Industry Experts
DUBLIN, Dec. 17, 2019 /PRNewswire/ -- The "Biosimilars: US Payer Insights (2019)" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma? Originator companies are fiercely defending their brands which has slowed new product introductions and limited clinicians' ability to build prescribing confidence with biosimilar products. While payers remain upbeat about biosimilars they are looking to pharma to deliver the evidence of safety and utility to educate and support a cautious clinical community.
What strategies are payers using to drive biosimilar usage? Will the FDA's guidelines on interchangeability accelerate the market? Why is competition essential in the biosimilar space? This detailed report, based on in-depth interviews with experienced US payers, reveals their insights on current trends, future developments and the practical steps pharma can take now.
Payers tackle key questions such as:
-- How confident are payers in reimbursing biosimilars and has this level
of confidence changed over the last 12 months?
-- What are the best methods of educating key stakeholders about
biosimilars and what needs to be the focus of such campaigns?
-- Are biosimilar developers making enough effort to understand payer goals
and objectives and what can they do to improve their engagement?
-- What are the arguments for non-medical switching from branded to
biosimilar products?
-- How much of a concern to payers is the 'rebate trap' and have anxieties
increased over the last 12 months?
-- In terms of real world evidence what are payers looking for and how
influential is it?
-- What do payers think of pharmacy-level substitution of branded biologics
for a biosimilar of the same molecule and why might this not be possible
countrywide?
Includes supportive case studies:
-- Amgen's controversial "Circle the Suffix" campaign
-- The Biosimilars Council and the APhA biosimilar education
-- Boehringer Ingelheim's content-driven
-- Learning from the UK - NHS resources for the launch of Humira
biosimilars
-- The PCMA's "Protect the Savings" campaign
-- How the success of Zarxio has improved confidence in biosimilars
-- Is the FDA's interchangeability requirement too stringent?
-- PBMs' unfair practices and their effect on biosimilar developers
-- Payer experiences of the introduction of biosimilar versions of Remicade
within the therapeutic area of
-- Payer experiences of the introduction of a biosimilar within the
therapeutic area of Cancer
What to expect:
-- A detailed report revealing payer ambitions for the US biosimilars
sector and the challenges it faces
-- An examination of 12 key issues which originator and biosimilar drug
developers need to understand and respond to
-- 20 targeted questions put to experienced payers
-- Their perceptive responses that provided 47 insights supported by 199
directly quoted comments
Why buy now?
This report reveals the real world insights of knowledgeable experts to analyse in detail key commercial and market trends that pharma management need to understand if they are to effectively respond to critical developments. This highly-focused report:
-- Is based on primary research with experts
-- Presents clear insights and actionable intelligence
-- Includes only the latest primary research and findings we don't recycle
content or use secondary sources
For more information about this report visit https://www.researchandmarkets.com/r/4qzjt7
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
